X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
HQP1351 (olverembatinib) is a third-generation BCR-ABL inhibitor. It is being developed for the treatment of previously treated adult patients with chronic-phase chronic myeloid leukemia (CML-CP).
Lead Product(s): Olverembatinib
Therapeutic Area: Oncology Product Name: HQP1351
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 13, 2024
Details:
HQP1351 (olverembatinib), a novel, small-molecule, orally administered 3G BCR-ABL1 inhibitor, received breakthrough therapy designation by NMPA for olverembatinib for the treatment of patients with naïve philadelphia chromosome-positive acute lymphoblastic leukemia.
Lead Product(s): Olverembatinib
Therapeutic Area: Oncology Product Name: HQP1351AG301
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 17, 2023
Details:
The two companies will jointly conduct Phase III of the Bcl-2 inhibitor, APG-2575 (lisaftoclax), in combination with AstraZeneca's BTK inhibitor, Calquence (acalabrutinib), in treatment-naive patients with first-line chronic lymphocytic leukemia/small lymphocytic lymphoma.
Lead Product(s): Lisaftoclax,Acalabrutinib
Therapeutic Area: Oncology Product Name: APG-2575
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: AstraZeneca
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration October 15, 2023
Details:
APG-2575 (lisaftoclax) is a novel, orally administered small molecule Bcl-2 selective inhibitor developed by Ascentage Pharma to treat a range of malignancies by selectively blocking the antiapoptotic protein Bcl-2, thus restoring the normal apoptosis process in cancer cells.
Lead Product(s): Lisaftoclax
Therapeutic Area: Oncology Product Name: APG-2575
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 06, 2023
Details:
HQP1351 (olverembatinib), a novel, small-molecule, orally administered 3G BCR-ABL1 inhibitor, received breakthrough therapy designation by NMPA for olverembatinib for the treatment of patients with naïve philadelphia chromosome-positive acute lymphoblastic leukemia.
Lead Product(s): Olverembatinib
Therapeutic Area: Oncology Product Name: HQP1351
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Shenzhen Second People's Hospital
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 05, 2023
Details:
HQP1351 (olverembatinib) is a novel, small-molecule, orally administered 3G BCR-ABL1 inhibitor and received Breakthrough Therapy Designation by NMPA for Olverembatinib for the treatment of patients with SDH-deficient gastrointestinal stromal tumor.
Lead Product(s): Olverembatinib
Therapeutic Area: Oncology Product Name: HQP1351
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Recipient: Innovent Biologics
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 02, 2023
Details:
HQP1351 (olverembatinib), a third-generation BCR-ABL inhibitor received Breakthrough Therapy Designation (BTD) for the treatment of patients with succinate dehydrogenase (SDH)-deficient gastrointestinal stromal tumor (GIST) who had received first-line treatment.
Lead Product(s): Olverembatinib
Therapeutic Area: Oncology Product Name: HQP1351
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Innovent Biologics
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 30, 2023
Details:
HQP1351 (olverembatinib) is a novel, small-molecule, orally administered 3G BCR-ABL1 inhibitor. It was approved in China for the treatment of adult patients with TKI-resistant chronic-phase chronic myeloid leukemia (CML-CP) or accelerated-phase CML (CML-AP).
Lead Product(s): Olverembatinib
Therapeutic Area: Oncology Product Name: HQP1351
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 18, 2023
Details:
APG-5918 is an orally active, potent and highly selective small molecule inhibitor of EED protein under development by Ascentage Pharma. APG-5918 is the first Chinese original EED inhibitor to enter the clinical stage.
Lead Product(s): APG-5918
Therapeutic Area: Oncology Product Name: APG-5918
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 10, 2022
Details:
Lisaftoclax (APG-2575) is a Novel BCL-2 Inhibitor, selectively binds BCL-2 (Ki < 0.1 nM), disrupts BCL-2:BIM complexes, and compromises mitochondrial outer membrane potential, culminating in BAX/BAK-dependent, caspase-mediated apoptosis.
Lead Product(s): Lisaftoclax,Acalabrutinib
Therapeutic Area: Oncology Product Name: APG-2575
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 03, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
